Home > Insider Trading > Filing (0000899243-21-043033)

Filing Details

Accession Number:: 0000899243-21-043033
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-11-04 17:00:37
Reporting Period:: 2021-11-02

Accepted Time:: 2021-11-04 17:00:37
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1501796	Aura Biosciences Inc.	AURA	Biological Products, (No Disgnostic Substances) (2836)	320271970

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1690310	Medicxi Growth I Lp	C/O Intertrust Fund Services (Jersey) Limited, 44 Esplanade St. Helier Y9 JE4 9WG	No	No	Yes	No
1715578	Medicxi Growth Co-Invest I Lp	C/O Intertrust Fund Services (Jersey) Limited, 44 Esplanade St. Helier Y9 JE4 9WG	No	No	Yes	No
1715579	Ltd (Jersey) Management Ventures Medicxi	C/O Intertrust Fund Services (Jersey) Limited, 44 Esplanade St. Helier Y9 JE4 9WG	No	No	Yes	No
1715600	Ltd Gp I Growth Medicxi	C/O Intertrust Fund Services (Jersey) Limited, 44 Esplanade St. Helier Y9 JE4 9WG	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-11-02	2,275,827	$0.00	2,275,827	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-11-02	693,525	$14.00	2,969,352	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2021-11-02	54,065	$0.00	54,065	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-11-02	16,475	$14.00	70,540	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series D-1 Convertible Preferred Stock	Disposition	2021-11-02	1,650,676	$0.00	1,650,676	$0.00
Common Stock	Series D-2 Convertible Preferred Stock	Disposition	2021-11-02	373,606	$0.00	373,606	$0.00
Common Stock	Series E Convertible Preferred Stock	Disposition	2021-11-02	251,545	$0.00	251,545	$0.00
Common Stock	Series D-1 Convertible Preferred Stock	Disposition	2021-11-02	39,214	$0.00	39,214	$0.00
Common Stock	Series D-2 Convertible Preferred Stock	Disposition	2021-11-02	8,876	$0.00	8,876	$0.00
Common Stock	Series E Convertible Preferred Stock	Disposition	2021-11-02	5,975	$0.00	5,975	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The number of shares of Common Stock contained in Column 4 of Table I, Rows 1 and 3, are the combined total of each share of Series D-1 Convertible Preferred Stock, Series D-2 Convertible Preferred Stock and Series E Convertible Preferred Stock which immediately prior to the closing of the Issuer's initial public offering ("IPO") converted into shares of the Issuer's Common Stock, on a 13.7-for one basis without payment or further consideration and had no expiration date.
Held by Medicxi Growth I LP, a Jersey limited partnership ("Medicxi Growth I"). Medicxi Growth I GP Limited, a Jersey limited liability company ("MGI GP"), is the sole managing general partner of Medicxi Growth I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company ("Medicxi Manager") is the sole manager of Medicxi Growth I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose.
Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership ("Medicxi Growth Co-Invest I"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose.
Immediately prior to the closing of the IPO, the Series D-1 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-1 Convertible Preferred Stock had no expiration date.
Immediately prior to the closing of the IPO, the Series D-2 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-2 Convertible Preferred Stock had no expiration date.
Immediately prior to the closing of the IPO, the Series E Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series E Convertible Preferred Stock had no expiration date.